

Special Issue

Novel Concepts and Technologies in Vaccine Development for Emerging Pathogens

Message from the Guest Editors

Vaccination remains one of the most effective strategies for preventing and controlling infectious diseases. Due to biotechnological and molecular techniques, vaccine antigen production has realized significant advancements. This Special Issue aims to compile cutting-edge research and reviews focusing on innovative methods and technologies for producing antigens used in vaccination. We invite original research articles and comprehensive reviews on the following topics: recombinant protein antigens, peptide-based vaccines, DNA and RNA vaccines, virus-like particles (VLPs) and adjuvant development. We invite researchers and practitioners from academia and industry to submit original research articles, comprehensive reviews and insightful commentaries notably on the following topics:

- Recombinant Protein Antigens
- Peptide-Based Vaccines
- DNA and RNA Vaccines
- Virus-Like Particles (VLPs)
- Adjuvant Development

Guest Editors

Dr. Wildriss Viranaicken

PIMIT, Processus Infectieux en Milieu Insulaire Tropical, Université de La Réunion, INSERM UMR 1187, CNRS 9192, IRD 249, Plateforme CYROI, 97490 Sainte-Clotilde, Ile de La Réunion, France

Dr. Grégoire Lebeau

PIMIT, Processus Infectieux en Milieu Insulaire Tropical, Université de La Réunion, INSERM UMR 1187, CNRS 9192, IRD 249, Plateforme CYROI, 97490 Sainte-Clotilde, Ile de La Réunion, France

Deadline for manuscript submissions

closed (31 March 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/211753

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).